2021 Angel Pharmaceuticals, All rights reserved
Angel is dedicated to advancing science and medicine to improve patient outcomes. We prioritize the swift and effective sharing of our preclinical and clinical discoveries with the scientific, medical, and patient communities, as we firmly believe that knowledge dissemination benefits all.
Our team of scientists and clinical investigators has published the following studies in leading peer-reviewed journals and presented key findings at prestigious scientific conferences.
ITK-targeted immune remodeling enhanced the efficacy of anti-CD19 CAR-T cell therapy
Zhenjun Li, Liangcheng Lv, Xiaoyu Yao, Zhiwei Feng, Yan Xie, Kecheng Li, Feifei Qi, Mei Yang, Jingwen Wang, Tao Pan, Xinghua Li, Haiyan Chen, Jing Wang, Yanping Ding, Jun Zhu, Yuqin Song, Xiaomin Wang & Ning Ding
Article in Press :Cell Death Discovery
ITK-targeted immune remodeling enhanced the efficacy of anti-CD19 CAR-T cell therapy
Dynamic Single-Cell Profiling Reveals Novel Immune Regulatory Mechanism of ITKi Soquelitinib in Refractory T Cell Lymphoma
Ning Ding1, Yan Xie1, Yong Guo2, Kecheng Li2, Tingting DU1, Zhenjun Li1, Yuejiao Li1, Jiaowu Cao1, Dingyao Hu1, Lih-Yun Hsu3, Richard Miller3, Jun Zhu1 and Yuqin Song, MD1
1Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China; 2Angel Pharmaceuticals Co., Ltd., Jiaxing, China; 3Corvus Pharmaceuticals Inc, Burlingame, United States of America
Poster presentation at American Society of Hematology (ASH) 2023
ITK Inhibitor induces Th1 skewing and host anti-tumor response mediated by CD8+ TEMRA cells in refractory T cell lymphoma patients
N. Ding1, Y. Xie1, J. Reneau2, R. Miller3, S. Mahabhashyam3, L. Hsu3, Y. Guo4, K.C. Li4, T. Du1, L. Mi1, N. Lin1, J. Cao1, D. Hu1, D. Wang1, Y. Li1, Z. Li1, J. Zhu1, Y. Song1
1Peking University Cancer Hospital, Department of Lymphoma, Beijing, China; 2The Ohio State University and Wexner Medical Center, Columbus, Ohio, United States of America; 3Corvus Pharmaceuticals Inc., Burlingame, California, United States of America; 4Angel Pharmaceuticals Co., Ltd., Jiaxing, China
Poster presentation at the International Conference on Malignant Lymphoma (ICML) Meeting
ITK Inhibitor Induces Dose-Dependent Th1 Skewing in Normal T Cells and is Active in Refractory T Cell Lymphomas
Yuqin Song1, Ning Ding1, Dok Hyun Yoon2, John Reneau3, Ryan Wilcox4, Won Seog Kim5, Youn Kim6, Michael Khodadoust6, Tatyana Feldman7, Costas K Yannakou8, Pratyush Giri9, Jonathan Brammer3, Lih-Yun Hsu10, Hongwei Yuan10, Erik Verner11, Suresh Mahabhashyam10, Richard Miller10,11
1Peking University Cancer Hospital & Institute, Beijing, China; 2Asan Medical Center, Seoul, South Korea; 3The Ohio State University and Wexner Medical Center, Columbus, OH, USA; 4University of Michigan, Ann Arbor, MI, USA; 5Samsung Medical Center, Seoul, South Korea; 6Stanford Cancer Institute, Stanford, CA, USA; 7John Theurer Cancer Center at HMH, Hackensack, NJ, USA; 8Epworth HealthCare, Melbourne, Victoria, Australia; 9Royal Adelaide Hospital, Adelaide, South Australia, Australia; 10Corvus Pharmaceuticals Inc, Burlingame, CA, USA; 11Angel Pharmaceuticals Co., Ltd, Jiaxing, China
Poster Presentation at the 2022 American Society of Hematology Annual Meeting